Whole kidney engineering for clinical translation

Ick Hee Kim, In K ap Ko, Anthony Atala, James J. Yoo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Renal transplantation is currently the only definitive treatment for end-stage renal disease; however, this treatment is severely limited by the shortage of implantable kidneys. To address this shortcoming, development of an engineered, transplantable kidney has been proposed. Although current advances in engineering kidneys based on decellularization and recellularization techniques have offered great promises for the generation of functional kidney constructs, most studies have been conducted using rodent kidney constructs and short-term in-vivo evaluation. Toward clinical translations of this technique, several limitations need to be addressed.

RECENT FINDINGS: Human-sized renal scaffolds are desirable for clinical application, and the fabrication is currently feasible using native porcine and discarded human kidneys. Current progress in stem cell biology and cell culture methods have demonstrated feasibility of the use of embryonic stem cells, induced pluripotent stem cells, and primary renal cells as clinically relevant cell sources for the recellularization of renal scaffolds. Finally, approaches to long-term implantation of engineered kidneys are under investigation using antithrombogenic strategies such as functional reendothelialization of acellular kidney matrices.

SUMMARY: In the field of bioengineering, whole kidneys have taken a number of important initial steps toward clinical translations, but many challenges must be addressed to achieve a successful treatment for the patient with end-stage renal disease.

Original languageEnglish (US)
Pages (from-to)165-170
Number of pages6
JournalCurrent Opinion in Organ Transplantation
Volume20
Issue number2
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Biomedical Engineering
Kidney
Chronic Kidney Failure
Induced Pluripotent Stem Cells
Bioengineering
Embryonic Stem Cells
Kidney Transplantation
Cell Biology
Rodentia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Whole kidney engineering for clinical translation. / Kim, Ick Hee; Ko, In K ap; Atala, Anthony; Yoo, James J.

In: Current Opinion in Organ Transplantation, Vol. 20, No. 2, 01.04.2015, p. 165-170.

Research output: Contribution to journalArticle

Kim, Ick Hee ; Ko, In K ap ; Atala, Anthony ; Yoo, James J. / Whole kidney engineering for clinical translation. In: Current Opinion in Organ Transplantation. 2015 ; Vol. 20, No. 2. pp. 165-170.
@article{3eed4ee790d64bb8bade596b1536e792,
title = "Whole kidney engineering for clinical translation",
abstract = "PURPOSE OF REVIEW: Renal transplantation is currently the only definitive treatment for end-stage renal disease; however, this treatment is severely limited by the shortage of implantable kidneys. To address this shortcoming, development of an engineered, transplantable kidney has been proposed. Although current advances in engineering kidneys based on decellularization and recellularization techniques have offered great promises for the generation of functional kidney constructs, most studies have been conducted using rodent kidney constructs and short-term in-vivo evaluation. Toward clinical translations of this technique, several limitations need to be addressed.RECENT FINDINGS: Human-sized renal scaffolds are desirable for clinical application, and the fabrication is currently feasible using native porcine and discarded human kidneys. Current progress in stem cell biology and cell culture methods have demonstrated feasibility of the use of embryonic stem cells, induced pluripotent stem cells, and primary renal cells as clinically relevant cell sources for the recellularization of renal scaffolds. Finally, approaches to long-term implantation of engineered kidneys are under investigation using antithrombogenic strategies such as functional reendothelialization of acellular kidney matrices.SUMMARY: In the field of bioengineering, whole kidneys have taken a number of important initial steps toward clinical translations, but many challenges must be addressed to achieve a successful treatment for the patient with end-stage renal disease.",
author = "Kim, {Ick Hee} and Ko, {In K ap} and Anthony Atala and Yoo, {James J.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1097/MOT.0000000000000173",
language = "English (US)",
volume = "20",
pages = "165--170",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Whole kidney engineering for clinical translation

AU - Kim, Ick Hee

AU - Ko, In K ap

AU - Atala, Anthony

AU - Yoo, James J.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - PURPOSE OF REVIEW: Renal transplantation is currently the only definitive treatment for end-stage renal disease; however, this treatment is severely limited by the shortage of implantable kidneys. To address this shortcoming, development of an engineered, transplantable kidney has been proposed. Although current advances in engineering kidneys based on decellularization and recellularization techniques have offered great promises for the generation of functional kidney constructs, most studies have been conducted using rodent kidney constructs and short-term in-vivo evaluation. Toward clinical translations of this technique, several limitations need to be addressed.RECENT FINDINGS: Human-sized renal scaffolds are desirable for clinical application, and the fabrication is currently feasible using native porcine and discarded human kidneys. Current progress in stem cell biology and cell culture methods have demonstrated feasibility of the use of embryonic stem cells, induced pluripotent stem cells, and primary renal cells as clinically relevant cell sources for the recellularization of renal scaffolds. Finally, approaches to long-term implantation of engineered kidneys are under investigation using antithrombogenic strategies such as functional reendothelialization of acellular kidney matrices.SUMMARY: In the field of bioengineering, whole kidneys have taken a number of important initial steps toward clinical translations, but many challenges must be addressed to achieve a successful treatment for the patient with end-stage renal disease.

AB - PURPOSE OF REVIEW: Renal transplantation is currently the only definitive treatment for end-stage renal disease; however, this treatment is severely limited by the shortage of implantable kidneys. To address this shortcoming, development of an engineered, transplantable kidney has been proposed. Although current advances in engineering kidneys based on decellularization and recellularization techniques have offered great promises for the generation of functional kidney constructs, most studies have been conducted using rodent kidney constructs and short-term in-vivo evaluation. Toward clinical translations of this technique, several limitations need to be addressed.RECENT FINDINGS: Human-sized renal scaffolds are desirable for clinical application, and the fabrication is currently feasible using native porcine and discarded human kidneys. Current progress in stem cell biology and cell culture methods have demonstrated feasibility of the use of embryonic stem cells, induced pluripotent stem cells, and primary renal cells as clinically relevant cell sources for the recellularization of renal scaffolds. Finally, approaches to long-term implantation of engineered kidneys are under investigation using antithrombogenic strategies such as functional reendothelialization of acellular kidney matrices.SUMMARY: In the field of bioengineering, whole kidneys have taken a number of important initial steps toward clinical translations, but many challenges must be addressed to achieve a successful treatment for the patient with end-stage renal disease.

UR - http://www.scopus.com/inward/record.url?scp=84930834438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930834438&partnerID=8YFLogxK

U2 - 10.1097/MOT.0000000000000173

DO - 10.1097/MOT.0000000000000173

M3 - Article

VL - 20

SP - 165

EP - 170

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 2

ER -